DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/mzjdmv/lung_cancer_drug) has announced the addition of the "Lung Cancer Drug Pipeline Update 2013" report to their offering.
High unmet needs still persist for this tumor type and despite two decades of extensive R&D and chemotherapy use, the median overall survival of NSCLC patient's remains below 12 months. Mesothelioma is rarer, although incidence is expected to increase in the coming years in Europe and Japan given the heavy use of asbestos in the 1970s and long latency period of the disease.
There are today 351 companies plus partners developing 470 lung cancer drugs in 552 developmental projects in cancer. In addition, there are 11 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 206 drugs. Lung Cancer Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 300 different targets. All included targets have been cross-referenced for the presence of mutations associated with human cancer. To date 293 out of the 296 studied drug targets so far have been recorded with somatic mutations. The software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information. All drugs targets are further categorized on in the software application by 68 classifications of molecular function and with pathway referrals to BioCarta, KEGG, NCI-Nature and NetPath.
Drug Pipeline Update at a Glance
Investigators
Includes more than 351 principal companies plus their collaborators. There is direct access from inside the application to web pages of all principal companies.
Developmental stage
This Drug Pipeline Update contains 470 lung cancer drugs in development, which have a total of 552 developmental projects in cancer. In addition there are suspended and ceased drugs
Indications
Included lung cancer drugs are also in development for 212 other indications, where of 113 are different cancer indications.
Biological Structures
The identity of available biological structures on 211 drug targets was retrieved from the RCSB Protein Databank for you to easily review the 3738 structures available today among drug targets.
For more information visit http://www.researchandmarkets.com/research/mzjdmv/lung_cancer_drug
About Research and Markets
Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
